MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy
暂无分享,去创建一个
P. Álvarez | J. Prados | C. Melguizo | R. Ortiz | A. Aránega | F. Rodríguez-Serrano | A. Concha | R. Madeddu | G. Perazzoli | J. Oliver | B. Gónzalez | Rodrigo López